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Background and aims: To assess the relationship between the extent and phenotype of coronary
atherosclerosis, as assessed by in-vivo grayscale and radiofrequency intravascular ultrasound (IVUS), and
circulating Troponin levels in patients with established stable coronary artery disease (CAD).
Methods: In this single-center, cross-sectional analysis, high-sensitivity Troponin T (hsTnT) was
measured and IVUS was performed in a predeﬁned non-stenotic segment of a non-culprit coronary
artery in 231 patients with stable CAD undergoing elective angiography.
Results: HsTnT was detectable (>3 pg/mL) in 212 patients (92%) and a concentration above 14 pg/mL was
observed in 19.5%. Normalised segmental plaque volumes were positively associated with hsTnT levels
(25.0 mm3 increase in segmental plaque volume per SD increase in ln-transformed hsTnT, 95% CI: 6.0
e44.0, p ¼ 0.010). Higher hsTnT levels were measured in patients with a virtual histology derived thin-
cap ﬁbroatheroma (VH-TCFA, adj. odds ratio for presence of VH-TCFA ¼ 1.52 per SD increase in ln-
transformed hsTnT, 95% CI: 1.10e2.11, p ¼ 0.011). Patients with a VH-TCFA had a 2-fold increased
prevalence of hsTnT concentration 14 pg/mL (adj. OR 2.35, 95% CI: 1.12e4.91, p ¼ 0.024). In addition, a
3-fold increased prevalence of hsTnT concentration 14 pg/mL was observed in patients with a VH-TCFA
with a lesional plaque volume higher than the median (adj. OR 3.36, 95% CI: 1.44e7.84, p ¼ 0.005).
Conclusions: Segmental plaque volume and presence of VH-TCFA lesions are associated with higher
circulating hsTnT concentrations in stable CAD patients. Subclinical plaque rupture or erosion and distal
embolisation may be hypothesized as a potential pathophysiological mechanism with respect to
Troponin elevation and its relation with adverse outcome in this patient population.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cardiac Troponin is the preferred biochemical marker for diag-
nostic use in patients with a suspected acute coronary syndrome
(ACS) [1]. However Troponin elevation also has prognosticiology, Clinical Epidemiology
tterdam, The Netherlands.
sma).
r Ireland Ltd. This is an open accesrelevance in patients without chestpain at rest. In ambulatory pa-
tients with established stable coronary artery disease (CAD) as
enrolled in the Heart and Soul study, Troponin T (TnT) was
detectable in 6% of the study populationwhen using a conventional
TnT assay [2]. With the recent introduction of the high-sensitivity
Troponin T assay (hsTnT), circulating TnT levels could be detected
in 81% of the same study population of ambulatory patients with
stable CAD [3]. In these 984 patients, higher hsTnT levels were,
amongst others, associated with greater inducible ischemia, worse
treadmill exercise capacity and lower left ventricular ejections article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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dictive of cardiovascular mortality, myocardial infarction (MI) and
heart failure after adjustment for abnormalities in cardiac structure
and function [3]. Similar associations between hsTnT elevation and
increased risk for major adverse cardiovascular events (MACE) in
ambulatory patients with stable CAD were also observed in post-
hoc analyses of the PEACE trial [4], the BARI-2D trial [5] and in a
study of stable CAD patients participating in an in-hospital reha-
bilitation program [6].
Yet, despite these positive associations between hsTnTand long-
term outcome, currently no data are available on the association
between coronary plaque characteristics and hsTnT elevation in
patients with stable CAD. However, the assessment of such a
possible relationship is imperative in order to understand the eti-
ology of the Troponin elevation, as well as to gain insight into the
mechanisms by which Troponin elevation exerts its adverse impact
on prognosis [7]. Hence, our objectivewas to assess the relationship
between coronary plaque characteristics and phenotype, as
assessed by in-vivo grayscale and radiofrequency intravascular ul-
trasound (IVUS), and Troponin levels in patients with established
stable CAD.
2. Methods
2.1. Study population
The design, detailed inclusion and exclusion criteria and initial
results of the prospective, single-center, observational, European
Collaborative Project on Inﬂammation and Vascular Wall Remod-
eling in Atherosclerosis e Intravascular Ultrasound (ATHEROR-
EMO-IVUS) study have been described previously [8,9]. The study
enrolled 581 patients, but for the current analysis 318 ACS patients
were omitted, since hsTnT levels in those patients are obviously
more determined by intracoronary thrombosis due to acute plaque
rupture of a culprit vessel and subsequent varying degrees of
myocardial necrosis, and to a much lesser extent by the vessel
characteristics of a non-culprit vessel, as investigated in the
ATHEROREMO-IVUS study. All of the patients had stable angina,
were ambulatory and presented at the discretion of the referring
physician for a planned and elective admission for angiography
after consenting at the out-patient clinic. None of the patients were
admitted for acute chest pain or dynamic ECG changes at rest. Pa-
tients with an indication for angiography other than stable angina
pectoris (SAP, n ¼ 9) and those with known confounders of
Troponin elevation [10] such as history of heart failure (n ¼ 13) or
renal insufﬁciency (n ¼ 19, nine of whom had concomitant heart
failure) were omitted.
The ATHEROREMO-IVUS study was approved by the medical
ethics committee of the Erasmus MC. The study was performed in
accordance with the criteria described in the declaration of Hel-
sinki. Written informed consent was obtained from all included
patients. ATHEROREMO-IVUS is registered in ClinicalTrials.gov,
number NCT01789411.
2.2. High-sensitivity Troponin T
Blood samples were drawn from the 6 French arterial sheath
prior to catheter insertion. TnT was measured with both a con-
ventional fourth generation assay and a high-sensitivity assay on
the Cobas 8000 modular analyzer platform (Roche Diagnostics
GmbH, Mannheim, Germany). The diagnostic range of the high-
sensitivity assay is 3e10.000 pg/mL with a coefﬁcient of variation
of 9% at the 99th percentile value of 14 pg/mL [11]. Laboratory
personnel were blinded for baseline patient characteristics and
IVUS data.2.3. Intracoronary ultrasound imaging
Subsequent to the standard angiography and PCI (when appli-
cable), IVUS of a non-culprit coronary artery was performed with
the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, CA,
USA) [9]. The IVUS target segment of the non-culprit coronary ar-
tery was required to be at least 40 mm in length and without sig-
niﬁcant luminal narrowing (<50% stenosis) as assessed by on-line
angiography. Selection of the non-culprit vessel was predeﬁned in
the study protocol. The IVUS images were analyzed off-line by an
independent core laboratory (Cardialysis BV, Rotterdam, the
Netherlands). The core laboratory personnel were blinded for
baseline patient characteristics and TnT and hsTnT levels.
Plaque burden was deﬁned as plaque and media cross-sectional
area divided by external elastic membrane cross-sectional area X
100. A coronary lesion was deﬁned as a segment with a plaque
burden of more than 40% in at least 3 consecutive frames. The
composition of the atherosclerotic lesions was characterized into 4
different tissue types with the use of IVUS virtual histology (IVUS-
VH): ﬁbrous, ﬁbro-fatty, dense calcium and necrotic core. Three
types of high-risk lesions were identiﬁed: 1. Virtual histology-based
thin-cap ﬁbroatheroma (VH-TCFA) lesions, deﬁned as a lesion with
presence of >10% conﬂuent necrotic core in direct contact with the
lumen; 2. lesions with a plaque burden of 70%; 3. lesions with a
minimal luminal area of 4.0 mm2 [12,13]. VH-TCFAs were further
classiﬁed as having a high lesional plaque volume in case the pla-
que volume of that particular VH-TCFA was above the median
plaque volume of all lesions classiﬁed as VH-TCFA.
2.4. Statistical analysis
Normally distributed continuous variables are presented as
mean ± standard deviation (SD). Non-normally distributed
continuous variables are presented as median and interquartile
range (IQR). Categorical variables are presented in numbers and
percentages. Linear regressionwas used to evaluate the association
between segmental plaque volume, plaque burden, plaque tissue
types and natural logarithm (ln)-transformed hsTnT concentration
(ln-transformation was performed in order to maintain homoge-
neity of variance and normality of the (error) distribution).
Segmental plaque and vessel volume were normalised for the
imaged segment length (normalised plaque volume ¼ plaque vol-
ume/imaged segment length * median segment length of study
population). Logistic regression was used to examine the associa-
tion between hsTnT concentration and presence of high-risk cor-
onary lesions (as dependent). Determinants of a hsTnT
concentration above the clinically used 99th percentile in an
apparently healthy reference population of 14 pg/mL [11], were also
assessed with logistic regression. Multivariable analyses accounted
for confounding by age, gender, hypercholesterolemia, diabetes,
glomerular ﬁltration rate, hypertension, smoking status, family
history of CAD, history of MI, prior PCI, prior coronary artery bypass
grafting (CABG), stroke and peripheral artery disease (PAD). Crude
and adjusted odds ratios (OR) are presented with 95% conﬁdence
intervals. When necessary to assure parsimony of the logistic
regression models, adjustment according to a propensity score
(using the same confounders as mentioned above) was used
[14,15]. All statistical tests were two-sided with a type I error level
of 0.05. Analyses were performed with IBM SPSS statistics version
21.0.
3. Results
Between October 24, 2008 and January 28, 2011, a total of 231
patients with stable angina pectoris were enrolled prior to coronary
R.M. Oemrawsingh et al. / Atherosclerosis 247 (2016) 135e141 137angiography. Mean age was 63.6 ± 9.9 years. Men constituted 77%
of the study population. A PCI was performed in 85% of the patients
during the index coronary angiography (Table 1).
Troponin T was detectable in 5.8% of the study patients by the
conventional TnT assay (>0.01 mg/L). In contrast, the hsTnT assay
enabled detection (>3 pg/mL) in 212 patients (92%) and concen-
trations above the commonly used 99th percentile of a healthy
reference population of 14 pg/mL were observed in 45 (19.5%) of
our patients with manifest stable CAD. The 99th percentile in our
patient population was 88.7 pg/mL (Table 1 and Fig. 1).Fig. 1. Distribution of high-sensitivity Troponin T values in patients with stable
coronary artery disease. High-sensitivity Troponin T was measured in 231 patients
with stable coronary artery disease, undergoing an elective CAG. Blood samples were
drawn prior to catheterisation and/or PCI. Troponin concentrations were undetectably
low in 19 patients (8.2%). The datapoints of three patients with concentrations of 82, 91
and 192 pg/mL respectively are not shown in this histogram.3.1. Clinical determinants of high-sensitivity Troponin T
concentration
Age was the only determinant of hsTnT concentration (adjusted
(adj.) p < 0.001) (Fig. 2). There was no association with hsTnT
concentration and other baseline clinical variables, such as male
gender (adj. p ¼ 0.39), hypercholesterolemia (adj. p ¼ 0.28), dia-
betes (adj. p ¼ 0.96), glomerular ﬁltration rate (adj. p ¼ 0.08), hy-
pertension (adj. p ¼ 0.64), smoking status (adj. p ¼ 0.37), family
history (adj. p ¼ 0.60), history of MI (adj. p ¼ 0.57), PCI (adj.
p ¼ 0.60), CABG (adj. p ¼ 0.46), stroke (adj. p ¼ 0.61), or PAD (adj.
p ¼ 0.28), and the number of diseased coronary vessels on angi-
ography (adj. p ¼ 0.71).Table 1
Baseline characteristics.
Patient characteristics, N (%) N ¼ 231
Age (years± SD) 63.6 ± 9.9
Male 177 (76.6)
Diabetes Mellitus 48 (20.8)
Hypertension 141 (61.0)
Hypercholesterolemia 162 (70.1)
Smoking 42 (18.2)
Positive family history of CAD 137 (59.3)
Previous MI 93 (40.3)
Previous PCI 116 (50.2)
Previous CABG 7 (3.0)
Previous stroke 13 (5.6)
Peripheral artery disease 19 (8.2)
Glomerular Filtration Rate (ml/min, median [IQR]) 101.5 [80.2e123.0]
Out-patient clinic medication prior to angiography
Aspirin 218 (94.4)
Beta-blockers 181 (78.4)
ACE-inhibitors 139 (60.2)
Calcium antagonists 63 (27.3)
Oral nitrates 82 (35.5)
Statin 209 (90.5)
High-sensitivity Troponin T levels (pg/mL)
Median [IQR] 7.3 [4.9e12.1]
Mean 11.0
Standard deviation 15.5
Range 3.00e192.70
99th percentile 88.7
Procedural characteristics
Extent of coronary artery disease
No signiﬁcant stenosis 22 (9.5)
1-vessel disease 116 (50.2)
2-vessel disease 70 (30.3)
3-vessel disease 23 (10.0)
PCI/stent implantation 196 (84.8)
IVUS segment characteristics
Imaged coronary artery
Left anterior descending 76 (33.9)
Left circumﬂex 76 (32.9)
Right coronary artery 79 (34.2)
Segment length, mm [IQR] 43.8 [33.9e56.0]
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention;
CABG ¼ coronary artery bypass graft.
Fig. 2. Age in relation to high-sensitivity Troponin T concentration. The study
population was divided in age tertiles of 77 patients each. Multivariable analyses
accounted for confounding by age, gender, hypercholesterolemia, diabetes, glomerular
ﬁltration rate, hypertension, smoking status, family history of CAD, history of MI, prior
PCI, prior coronary artery bypass grafting, prior stroke and peripheral artery disease.
The histograms display the mean hsTnT concentration plus the standard error of the
mean.3.2. High-sensitivity Troponin T in association with segmental
plaque characteristics
The median segment length, as imaged with IVUS, was 43.8 mm
(Table 1). Normalised segmental plaque volumes were positively
associated with hsTnT levels (adjusted b ¼ 25.0 mm3 increase in
segmental plaque volume per SD increase in natural log-
transformed hsTnT, 95% CI: 6.0e44.0, p ¼ 0.010) (Table 2, Fig. 3
A). There was no signiﬁcant association between segmental pla-
que burden and hsTnT (adjusted b ¼ 0.92% increase in plaque
Table 2
High-sensitivity Troponin T concentration in relation to plaque characteristics in a non-culprit coronary artery in patients with stable coronary artery disease.
Total study population hsTnT <14 pg/mL hsTnT 14 pg/mL Adjusted P-value
(N ¼ 186) (N ¼ 45)
Segmental plaque characteristics Median [IQR]
Normalised vessel volume (mm3) 563.9 [439.2e755.0] 545.5 [421.2e691.3] 733.6 [494.8e917.5] 0.001
Normalised plaque volume (mm3) 234.0 [149.9e340.6] 215.2 [140.8e311.2] 271.1 [192.4e413.7] 0.008
Plaque burden (%) 40.4 [32.2e47.7] 39.8 [31.9e47.1] 43.2 [33.8e50.2] 0.41
Plaque composition Median [IQR]
Fibrous (%) 56.3 [49.4e63.8] 56.0 [49.5e65.1] 56.6 [48.6e60.3] 0.49
Fibro-fatty (%) 9.5 [6.3e13.4] 9.3 [5.8e13.4] 11.2 [8.1e14.2] 0.18
Dense calcium (%) 11.0 [5.9e16.1] 10.9 [5.7e16.1] 11.4 [6.3e17.1] 0.79
Necrotic core (%) 21.5 [17.2e25.3] 21.5 [16.7e25.7] 21.5 [18.4e24.9] 0.82
Lesion morphology N (%)
VH-TCFA 86 (37.2) 64 (34.4) 22 (48.9) 0.024
VH-TCFA with high lesional plaque volume 43 (18.6) 28 (15.1) 15 (33.3) 0.005
MLA  4.0 mm2 80 (34.6) 67 (36.0) 13 (28.9) 0.66
Plaque burden  70% 56 (24.2) 41 (22.0) 15 (33.3) 0.064
VH-TCFAs were classiﬁed as having a high lesional plaque volume in case the plaque volume of that particular VH-TCFA was above the median of all lesions classiﬁed as VH-
TCFA. Multivariable analyses accounted for confounding by age, gender, hypercholesterolemia, diabetes, glomerular ﬁltration rate, hypertension, smoking status, family
history of CAD, history of MI, prior PCI, coronary artery bypass grafting, stroke and peripheral artery disease (PAD).
HsTnT ¼ high-sensitivity Troponin T; VH-TCFA¼Virtual histology-derived Thin-cap ﬁbroatheroma; MLA ¼ minimal luminal area.
Fig. 3. High-sensitivity Troponin T concentration in relation to intravascular ultrasound characteristics. HsTnT, high-sensitivity Troponin T; PB, plaque burden; MLA, minimal
luminal area, VH-TCFA, Virtual histology-derived thin-cap ﬁbroatheroma. Panel A. High-sensitivity Troponin T per tertile of normalised plaque volume for the entire segment
(median length 43.8 mm, IQR: 33.9e56.0) as evaluated with grayscale intravascular ultrasonography (IVUS). Panel B. High-sensitivity Troponin T in relation to the presence of at
least one high-risk lesion type per patient. Thin-cap ﬁbroatheroma (TCFA) was assessed by means of radiofrequency IVUS.VH-TCFAs were classiﬁed as having a high lesional plaque
volume in case the plaque volume of that particular VH-TCFA was above the median plaque volume of all lesions classiﬁed as VH-TCFA. For both ﬁgures, multivariable analyses
accounted for confounding by age, gender, hypercholesterolemia, diabetes, glomerular ﬁltration rate, hypertension, smoking status, family history of CAD, history of MI, prior PCI,
coronary artery bypass grafting, stroke and peripheral artery disease. The histograms display the mean hsTnT concentration plus the standard error of the mean.
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CI: 0.61 to 2.44, p ¼ 0.24). However normalised segmental vessel
volumes were positively associated with hsTnT levels (adjusted
b ¼ 56.2 mm3 increase in segmental vessel volume per SD increasein natural log-transformed hsTnT, 95% CI: 21.9e90.5, p ¼ 0.001).
High-sensitivity Troponin T concentrations were not associated
with the segmental plaque distribution of the four tissue types as
assessed by IVUS virtual histology; ﬁbrous (adj. p ¼ 0.81), ﬁbro-
R.M. Oemrawsingh et al. / Atherosclerosis 247 (2016) 135e141 139fatty (adj. p ¼ 0.66), dense calcium (adj. p ¼ 0.37) and necrotic core
(adj. p ¼ 0.80).
3.3. High-sensitivity Troponin T in association with lesion
characteristics and morphology
With respect to lesion morphology, a VH-TCFA was observed in
86 (37%) patients (Table 2 and Supplementary appendix e Fig. 4).
Higher hsTnT levels weremeasured in patients with the presence of
a VH-TCFA (adj. OR for presence of VH-TCFA ¼ 1.52 per SD increase
in natural log-transformed hsTnT, 95% CI: 1.10e2.11, p ¼ 0.011)
(Fig. 3B).
In patients with hsTnT concentrations 14 pg/mL, a VH-TCFA
was observed in 49%. Hence, patients with a VH-TCFA had a 2-
fold increased prevalence of hsTnT concentration 14 pg/mL (adj.
OR 2.35, 95% CI: 1.12e4.91, p¼ 0.024) (Table 2). In addition, a 3-fold
increased prevalence of hsTnT concentration 14 pg/mL was
observed in patients with a VH-TCFA with a high lesional plaque
volume, i.e. a lesional plaque volume above the median of all le-
sions classiﬁed as VH-TCFA (adj. OR 3.36, 95% CI: 1.44e7.84,
p ¼ 0.005) (Table 2). Patients with a VH-TCFA with a high lesional
plaque volume also had higher hsTnT levels than patients with a
VH-TCFAwithout a high lesional plaque volume (16.8 pg/mL versus
9.4 pg/mL, p ¼ 0.03).
The relationship between lesions with a plaque burden 70%
and hsTnT was not statistically signiﬁcant (adj. OR ¼ 1.37 per SD
increase in natural log-transformed hsTnT, 95% CI: 0.99e1.90,
p ¼ 0.059) (Table 2 and Fig. 3B). No association was found between
lesions with a MLA 4.0 mm2 and hsTnT (adj. OR ¼ 0.83 per SD
increase in natural log-transformed hsTnT, 95% CI: 0.60e1.15,
p ¼ 0.26).
4. Discussion
This cross-sectional study is the ﬁrst to demonstrate an associ-
ation between elevated circulating Troponin levels and the extent
of coronary atherosclerosis and high-risk plaque phenotypes, as
assessed with intracoronary IVUS in a non-culprit coronary artery
in a broad population of stable CAD patients referred for elective
coronary angiography, as seen in everyday routine clinical practice.
In contrast to the conventional TnT assay, the hsTnT assay has
enabled detection of circulating TnT in themajority of patients with
stable CAD. Our ﬁnding that serum TnT levels were detectable in
only 5.8% of our stable CAD patients with the conventional fourth
generation TnTassay, versus detection in 92%when using the hsTnT
assay, corresponds to the results found in the Heart and Soul study
[3]. This expansion of serum TnT detection has led to more elabo-
rate risk prediction for the occurrence of MACE, as previously
demonstrated [3,4,6,16]. In a post-hoc analysis of the relatively low-
risk, stable CAD population of the PEACE trial, a graded increase in
the cumulative incidence of cardiovascular death (adjusted hazard
ratio (HR) per unit increase in the natural logarithm of the hsTnT
level 2.09; 95% conﬁdence interval [CI], 1.60 to 2.74) and of heart
failure (adjusted HR 2.20; 95% CI, 1.66 to 2.90) was seen in 3679
patients with stable CAD and preserved left ventricular function [4].
Similarly hsTnT was an independent predictor of death from car-
diovascular causes, myocardial infarction, or stroke in patients who
had both type 2 diabetes and stable ischemic heart disease in a
post-hoc analysis of the BARI-2D trial [5]. In addition, several pro-
spective, intracoronary imaging studies, primarily conducted in
ACS-patients, have reported an increased risk of repeat MACE in the
presence of TCFA as identiﬁed by IVUS-VH [17,18]. The presence of a
VH-TCFA was associated with a 3-fold increased risk of cardiovas-
cular mortality, cardiac arrest, MI, or rehospitalization due to un-
stable or progressive angina during 3.4 year follow-up of ACSpatients enrolled in the PROSPECT study [17]. More recently, similar
conclusions were drawn with respect to the complete
ATHEROREMO-IVUS study population comprising both stable CAD
and ACS patients [9]. The presence of a VH-TCFA, in a single target
segment without signiﬁcant luminal narrowing in a non-culprit
coronary artery, was independently associated with the compos-
ite of death and non-fatal ACS (7.5% vs. 3.0%; adjusted HR 2.51, 95%
CI 1.15e5.49) during 1-year follow-up [9].
Thus, both TnT elevation and high-risk intracoronary lesion
phenotypes as assessed by radiofrequency IVUS are recognized as
independent predictors of adverse cardiovascular outcome. Yet, to
our best knowledge, this is the ﬁrst study to describe the crosslink
between TnT elevation and the extent and phenotype of coronary
atherosclerosis as assessed by IVUS in a non-culprit coronary artery
in a population of patients with stable CAD.
Despite the increasing body of evidence showing adverse
outcome in case of Troponin elevation in ambulatory non-ACS
patients, only few reports have actually provided insight into a
possible mechanistic explanation for the Troponin elevation from
the perspective of coronary pathophysiology. A greater insight into
the pathophysiological mechanisms of Troponin elevation may also
increase our understanding of how Troponin elevation is linked to
adverse outcome in this patient population. In two studies evalu-
ating cardiac computed tomography, one in patients with stable
CAD and another in patients with acute chest pain presenting at the
emergency department, hsTnT levels were not associated with
stenosis severity, but were associated with the extent of coronary
plaque volume, which might support the hypothesis that chronic,
clinically silent rupture or erosion of non-calciﬁed plaques with
subsequent microembolisation may be a potential source of
myocardial injury and Troponin release [19,20]. However, given the
current state-of-the-art, cardiac computed tomography does not
allow for such extensive plaque phenotyping as grayscale and
radiofrequency IVUS. Therefore, our data showing that VH-TCFAs
are associated with Troponin release are essential for the line of
reasoning and hypothesis that microembolisation resulting from
silent plaque rupture or erosion might be a possible mechanistic
explanation for the elevated Troponin levels in these patients.
Indeed, autopsy studies have described TCFAs to be the plaques that
are most prone to superﬁcial erosion or rupture, consequently
leading to thrombus formation and distal (micro)embolisation [21].
Such plaque erosion or rupture has shown to be the major cause of
(fatal) acute MI, but not every plaque erosion or rupture invariably
leads to sufﬁcient thrombotic occlusion in order to provoke
symptoms of angina. It has been suggested that, at any given time,
approximately 15% of patients with stable CAD have ongoing
atherothrombotic plaque events compared to an annual incidence
of acute MI of approximately 5% [22]. Against this background,
hsTnT may serve as a biomarker for subclinical plaque rupture or
erosion leading to atherothrombosis, distal embolisation and
continuous low grade myocardial ischemia and cardiomyocyte
necrosis, even in presumably asymptomatic patients with stable
CAD.
Similarly, the association between the presence of VH-TCFA and
serum TnT elevation as found in the current population might also
be extended in order to hypothesize on the observation of subtle
TnT elevation in the general population and the associated
increased risk of MACE. In the Dallas Heart Study, a multi-ethnic,
population-based cohort study of individuals aged 30e65 years,
the prevalence of TnT levels above 3.0 pg/mL was 25.0% [16].
Interestingly, a graded increase in both cardiovascular and all-cause
mortality was seen across quintiles of TnT elevation in the entire
study cohort, but also in the subgroup analysis of 3222 patients
without cardiovascular or chronic kidney disease. A ﬁve-fold
increased risk for cardiovascular mortality was observed in case
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did not collect intracoronary IVUS data. Although speculative, an
increased prevalence of rupture-prone, high-risk lesion types, such
as TCFAs, might underlie the observation that participants without
symptoms of angina, i.e. without a ﬁxed and signiﬁcant coronary
luminal narrowing, did have both TnT elevation and a subsequent
increased risk of cardiovascular mortality.
Another important ﬁnding of our study was the association
between segmental plaque volume and Troponin concentration.
Similar observations were previously found in cardiac computed
tomography studies [19,20]. More recently, a post-hoc analysis of
the SATURN trial has demonstrated that a large plaque volume as
assessed with grayscale IVUS, in a non-culprit segment without
signiﬁcant stenosis, is associated with increased risk of MACE [23].
Hence, segmental plaque volume of a non-culprit coronary artery,
as assessed in ATHEROREMO-IVUS, may have prognostic impor-
tance. Segmental plaque volume may not only be linked to
Troponin concentration, but also to TCFA and plaque rupture, since
the majority of large stable plaques have evidence of previously
healed plaque rupture with incorporation of old thrombus into the
atheroma [21,22,24,25].
Troponinwas not related to segmental plaque burden (p¼ 0.24).
Levels seemed higher in patients with a lesion with plaque burden
70%, but the difference with patients with smaller plaque burden
did not reach statistical signiﬁcance (p ¼ 0.061). This may be due to
the fact that plaque burden is not a direct measure of three
dimensional plaque volume, but rather a two dimensional measure
that also accounts for arterial wall remodeling. The fact that both
normalized plaque and vessel volume were highly associated with
troponin levels may be seen as a conﬁrmation of positive remod-
eling in our dataset. Outward remodeling explains why presence of
large segmental plaque volumes do not necessarily relate to focal
lesional stenoses. The observation that stenosis severity, i.e. a MLA
4.0 mm2, was not related to hsTnTconcentration in our studymay
be regarded as a reconﬁrmation of the earlier mentioned cardiac
computed tomography studies [19,20,26]. Similarly, coronary ar-
tery calciumscore was not associated with hsTnT concentration
after multivariate adjustment in the in the Dallas Heart Study [16].
Such observations may indirectly support the hypothesis that not
ischemia due to luminal narrowing, but rather plaque rupture,
microembolisation and microcirculatory dysfunction is the patho-
physiological mechanism behind the increased circulating TnT
levels [27]. On the other hand, it has to be emphasized that 84.8% of
the patients in our analysis underwent a PCI and therefore had
signiﬁcant luminal stenosis in the culprit vessel. Our protocol was
based on non-culprit, single vessel imaging. Since the culprit ves-
sels were not imaged, all of our associations only apply to the an-
giographically non-stenotic non-culprit segments and no formal
conclusions can be drawn on stenosis severity elsewhere in the
coronary circulation and Troponin elevation.
Our study has several strengths. Our data were prospectively
obtained and, due to the broad inclusion criteria of ATHEROREMO-
IVUS, its conclusions seem applicable to a broad range of patients
with stable CAD. Of great importance is that IVUS evaluation was
performed in an independent, dedicated core lab with personnel
blinded for patient and TnT data. Similarly, Troponinwas measured
by laboratory personnel blinded for baseline patient characteristics
and IVUS data.
4.1. Study limitations
However, there are several limitations to our ﬁndings. A possible
limitation of our analysis might be the sample size, although this
study represents the only and therefore largest cohort of patients in
which the association between intracoronary IVUS plaquecharacteristics and circulating hsTnT was evaluated, so far.
Furthermore, ATHEROREMO-IVUS was a single center study by
virtue of design. External validation, preferably in a larger sample
size, is a fundamental prerequisite before ﬁnal conclusions may be
drawn. In our study, IVUS imaging took place of a pre-speciﬁed
single target segment of a non-culprit coronary artery of least
40 mm in length and without signiﬁcant luminal narrowing (<50%
stenosis) as assessed by on-line angiography. This approach was
developed under the assumption that such a non-stenotic segment
would adequately reﬂect coronary wall pathophysiology of the
larger coronary tree. Indeed, in a previous ATHEROREMO-IVUS
report, this assumption was conﬁrmed with respect to the pres-
ence of high-risk lesion types, such as VH-TCFA, and subsequent
increased risk of MACE [9]. In addition, the post-hoc analysis of the
SATURN trial also emphasized the prognostic importance of plaque
characteristics of a non-stenotic, non-culprit target segment [23].
Ideally, a conﬁrmatory replication of our association between
segmental plaque volume, presence of (VH-)TCFA and TnTelevation
should take place in a study enrolling patients with stable CAD for
three-vessel and left main IVUS assessment, since such an approach
would more precisely characterize the total coronary atheroscle-
rosis burden. IVUS-VH has been validated in vitro [28]. Sensitivities
and speciﬁcities for the detection of various plaque components
ranged from 72 to 99%, thus leaving room for misclassiﬁcation [28].
Furthermore, its ability to detect plaque erosion, rupture and
thrombus is limited given the current spatial resolution.
In conclusion, plaque volume and presence of VH-TCFAs, as
assessed with intracoronary IVUS in a non-culprit coronary artery
segment, are associated with higher circulating Troponin concen-
trations in a broad population of patients with stable CAD. Our data
are based on associations and cannot provide ﬁnal conclusions on
the exact etiology of Troponin elevation. However our ﬁndings may
generate the hypothesis that subclinical plaque rupture or erosion
of vulnerable plaques and subsequent intracoronary thrombosis
and distal embolisation may be the potential mechanism of action
with respect to Troponin elevation and its relation with adverse
outcome.Funding
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